600216 浙江医药
2024/09 - 九个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)8.5084.5495.98212.7069.240
总资产报酬率 ROA (%)6.4843.4084.3239.0776.877
投入资产回报率 ROIC (%)7.8454.1605.41111.3008.223

边际利润分析
销售毛利率 (%)40.05532.38734.47040.85141.539
营业利润率 (%)13.1744.8776.21812.92012.046
息税前利润/营业总收入 (%)13.0464.4375.58713.65612.571
净利润/营业总收入 (%)10.6653.5514.4689.6899.003

收益指标分析
经营活动净收益/利润总额(%)108.45130.963128.977103.75095.252
价值变动净收益/利润总额(%)-2.127-3.745-11.5008.10917.653
营业外收支净额/利润总额(%)-0.674-4.646-2.692-2.246-3.720

偿债能力分析
流动比率 (X)2.6072.2602.2941.9952.660
速动比率 (X)1.7821.4491.4851.3761.891
资产负债率 (%)20.99921.85621.90026.73323.527
带息债务/全部投入资本 (%)6.5817.4438.2849.517--
股东权益/带息债务 (%)1,407.4231,232.7411,100.412942.674770.747
股东权益/负债合计 (%)366.698344.798340.092262.045310.659
利息保障倍数 (X)-323.382-19.773-11.94313.38913.145

营运能力分析
应收账款周转天数 (天)55.85058.89560.80951.6360.000
存货周转天数 (天)125.261136.804130.911111.7830.000